References
- West CE, Renz H, Jenmalm MC, et al. The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies. J Allergy Clin Immunol. 2015;135(1):3–13. doi:https://doi.org/10.1016/j.jaci.2014.11.012.
- Raetz C, Reynolds CM, Trent MS, Bishop RE. Lipid A modification systems in gram-negative bacteria. Annu Rev Biochem. 2007;76:295–329. doi:https://doi.org/10.1146/annurev.biochem.76.010307.145803.
- Gnauck A, Lentle RG, Kruger MC. The characteristics and function of bacterial lipopolysaccharides and their endotoxic potential in humans. Int Rev Immunol. 2016;35(3):189–218. doi:https://doi.org/10.3109/08830185.2015.1087518.
- D Hennezel E, Abubucker S, Murphy LO, Cullen TW. Total lipopolysaccharide from the human gut microbiome silences toll-like receptor signaling. Msystems. 2017;2(6):e17-46. doi:https://doi.org/10.1128/mSystems.00046-17.
- Melania M, Lorenza P, Franco BG. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev. 2010;31(6):817–844.
- Clemente-Postigo M, Oliva-Olivera W, Coin-Aragüez L, Ramos-Molina B, Tinahones FJ. Metabolic endotoxemia promotes adipose dysfunction and inflammation in human obesity. Am J Physiol-Endocrinol Metabol. 2018;316(2):E319-E332.316.
- Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell. 2016;164(3):337–340. doi:https://doi.org/10.1016/j.cell.2016.01.013.
- Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65. doi:https://doi.org/10.1038/nature08821.
- Oa M, Fergus S. The gut flora as a forgotten organ. Embo Rep. 2006;7(7):688-693.
- Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635–1638. doi:https://doi.org/10.1126/science.1110591.
- Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol. 2014;16(7):1024–1033. doi:https://doi.org/10.1111/cmi.12308.
- Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes. 2012;3(4):279–288. doi:https://doi.org/10.4161/gmic.19625.
- Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091–1103. doi:https://doi.org/10.1136/gut.2008.165886.
- Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA. 2004;101(44):15718–15723.
- Stapleton PA, James ME, Goodwill AG, Frisbee JC. Obesity and vascular dysfunction. Pathophysiology. 2008;15(2):79–89. doi:https://doi.org/10.1016/j.pathophys.2008.04.007.
- Rotimi VO, Verghese TL, Al-Sweih N, Khodakhast FB, Ahmed K. Influence of five antianaerobic antibiotics on endotoxin liberation by gram-negative anaerobes. J Chemotherapy. 2000;12(1):40–47.
- Scheithauer TPM, Rampanelli E, Nieuwdorp M, et al. Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Front Immunol. 2020;11:571731 doi:https://doi.org/10.3389/fimmu.2020.571731.
- Fei N, Zhao L. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. ISME J. 2013;7(4):880–884. doi:https://doi.org/10.1038/ismej.2012.153.
- Pendyala S, Walker JM, Holt PR. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology. 2012;142(5):1100–1101.e2. doi:https://doi.org/10.1053/j.gastro.2012.01.034.
- Chen B, Tiegang L, Jingnan X, et al. Effect of high calorie diet on intestinal flora in LPS-induced pneumonia rats. Sci Rep. 2020;10(1):1701. doi:https://doi.org/10.1038/s41598-020-58632-0.
- Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470–1481. doi:https://doi.org/10.2337/db07-1403.
- Zhi C, Huang J, Wang J, et al. Connection between gut microbiome and the development of obesity. Eur J Clin Microbiol. 2019;38(11):1987-1998.
- Griffiths EA, Duffy LC, Schanbacher FL, et al. In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice. Digest Dis Sci. 20042004;49(4):579-589.
- Ewaschuk J, Endersby R, Thiel D, et al. Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis. Hepatology. 2007;46(3):841–850. doi:https://doi.org/10.1002/hep.21750.
- Chen J, Chen ZJ. PtdIns4P on dispersed trans-Golgi network mediates NLRP3 inflammasome activation. Nature. 2018;564(7734):71–76. doi:https://doi.org/10.1038/s41586-018-0761-3.
- Ciesielska A, Matyjek M, Kwiatkowska K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cell Mol Life Sci. 2021;78(4):1233–1229. doi:https://doi.org/10.1007/s00018-020-03656-y.
- Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5.
- Schumann RR. Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition molecule. Biochem Soc T. 2011;39
- Hersoug LG, Møller P, Loft S. Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. Obes Rev. 2016;17(4):297–312. doi:https://doi.org/10.1111/obr.12370
- Hamzic N, Tang Y, Eskilsson A, et al. Interleukin-6 primarily produced by non-hematopoietic cells mediates the lipopolysaccharide-induced febrile response. Brain Behav Immun. 2013;33:123–130. doi:https://doi.org/10.1016/j.bbi.2013.06.006.
- Pero R, Fico G, Scudiero O, Laneri S. Microbiota and LPS-induced obesity inflammation: therapeutic implications. 2018;
- Duparc T, Plovier H, Marrachelli VG, et al. Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism. Gut. 2017;66(4):620–632. doi:https://doi.org/10.1136/gutjnl-2015-310904.
- Yang Y, Lv J, Jiang S, et al. The emerging role of Toll-like receptor 4 in myocardial inflammation. Cell Death Dis. 2016;7(5):e2234–e2234. doi:https://doi.org/10.1038/cddis.2016.140.
- Hotamisligil G, Shargill N, Spiegelman B. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87–91. doi:https://doi.org/10.1126/science.7678183.
- Pam W, Klarlund PB. The anti-inflammatory effect of exercise. J Appl Physiol (Bethesda, Md.: 1985). 2005;98
- Brüünsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease - ScienceDirect. Immunol Allergy Clin. 2003;23(1):15–39. doi:https://doi.org/10.1016/S0889-8561(02)00056-5.
- Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol - Endocrinol Metabol. 2006;290:961–967. doi:https://doi.org/10.1152/ajpendo.00506.2005.
- Winkler G, Kiss S, Keszthelyi L, et al. Expression of tumor necrosis factor (TNF)-alpha protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-alpha, soluble serum TNF-receptor-2 concentrations and C-peptide level. Eur J Endocrinol. 2003;149:129–135. doi:https://doi.org/10.1530/eje.0.1490129.
- Clement K, Langin D. Regulation of inflammation-related genes in human adipose tissue. J Intern Med. 2007;262(4):422–430. doi:https://doi.org/10.1111/j.1365-2796.2007.01851.x.
- Lotte L, Birgitte L, Dorthe S, Peter P, Bengt S, Henriette P. Adipose tissue interleukin-18 mRNA and plasma interleukin-18: effect of obesity and exercise. Obesity (Silver Spring, Md.). 2007;15.
- Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome — an allostatic perspective. Biochimica et Biophysica Acta (BBA) - Mol Cell Biol Lipids. 2010;1801(3):338–349. doi:https://doi.org/10.1016/j.bbalip.2009.12.006.
- Muccioli GG, Naslain D, Bäckhed F, et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010;6(1):392. doi:https://doi.org/10.1038/msb.2010.46.
- Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489(7415):242–249. doi:https://doi.org/10.1038/nature11552.
- Shireen M, Christoph T. Role of metabolic endotoxemia in systemic inflammation and potential interventions. Front Immunol. 2021.
- Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev. 2010;31
- Akiba Y, Kaji I, Maruta K, Kaunitz JD. GLP-2 acutely ameliorates LPS-related intestinal permeability in rats. Gastroenterology. 2017;152(5):S506. doi:https://doi.org/10.1016/S0016-5085(17)31870-X.
- Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50(11):2374–2383. doi:https://doi.org/10.1007/s00125-007-0791-0.
- B EJ, Hugo D, Liisa M, et al. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am J Physiol. Gastrointestinal Liver Physiol. 2008;295.
- Zhang W, Gu Y, Chen Y, et al. Intestinal flora imbalance results in altered bacterial translocation and liver function in rats with experimental cirrhosis. Eur J Gastroen Hepat. 2010;22.
- Ko JS, Yang HR, Chang JY, Seo JK. Lactobacillus plantarum inhibits epithelial barrier dysfunction and interleukin-8 secretion induced by tumor necrosis factor-a. WJG. 2007;13(13):1962–1965. doi:https://doi.org/10.3748/wjg.v13.i13.1962.
- Naofumi Y, Tomoya Y, Shigenobu K, et al. A possible beneficial effect of Bacteroides on faecal lipopolysaccharide activity and cardiovascular diseases. Sci Rep-Uk. 2020;10.
- Shestakova EA, Ilyin AV, Shestakova MV, Dedov II. Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus. Terapevt Arkh. 2014;86:10–14.
- Maxime N, Annabelle T, Thomas G, et al. Glucagon-like peptide-1 is associated with poor clinical outcome, lipopolysaccharide translocation and inflammation in patients undergoing cardiac surgery with cardiopulmonary bypass. Cytokine. 2020;133.
- Lebrun LJ, Lenaerts K, Kiers D, et al. Enteroendocrine L cells sense LPS after gut barrier injury to enhance GLP-1 secretion. Cell Rep. 2017;21.
- Young-Sun L, Hee-Sook J. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediat Inflamm. 2016(2):3094642.
- Tsukasa N, Saori M, Shima K, Rintaro N, Kaoru T, Toshikatsu O. Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats. J Gastroen Hepatol. 2018;33(1):232-239.
- Kashihara H, Shimada M, Yoshikawa K, et al. Duodenal-Jejunal bypass maintains gut permeability by suppressing gut inflammation. Obes Surg. 2019;29(9):2745–2749. doi:https://doi.org/10.1007/s11695-019-03922-4.
- Bloch O, Perl SH, Lazarovitch T, et al. Hyper-activation of endogenous GLP-1 system to gram-negative sepsis is associated with early innate immune response and modulated by diabetes. Shock (Augusta, Ga.). 2021;55(6):796–805. doi:https://doi.org/10.1097/SHK.0000000000001683.
- Billeschou A, Hunt JE, Ghimire A, Holst JJ, Kissow H. Intestinal adaptation upon chemotherapy-induced intestinal injury in mice depends on GLP-2 receptor activation. Biomedicines. 2021;9(1):46-57. doi:https://doi.org/10.3390/biomedicines9010046.
- Maruta K, Takajo T, Akiba Y, et al. GLP-2 acutely prevents endotoxin-related increased intestinal paracellular permeability in rats. Digest Dis Sci. 2020;65(9):2605–2618
- Guan X, Karpen HE, Stephens J, et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology. 2006;130(1):150–164. doi:https://doi.org/10.1053/j.gastro.2005.11.005.
- Xie S, Liu B, Fu S, et al. GLP-2 suppresses LPS-induced inflammation in macrophages by inhibiting ERK phosphorylation and NF-κB activation. Cell Physiol Biochem. 2014;34(2):590–602. doi:https://doi.org/10.1159/000363025.
- Ejarque M, Sabadell-Basallote J, Beiroa D, et al. Adipose tissue is a key organ for the beneficial effects of GLP‐2 on glucose metabolism. Brit J Pharmacol. 2020:1–15.
- Amato A, Baldassano S, Mule F. GLP2: an underestimated signal for improving glycaemic control and insulin sensitivity. J Endocrinol. 2016;229(2):R57–R66. doi:https://doi.org/10.1530/JOE-16-0035.
- Hwang SJ, Kim Y, Park Y, Lee H, Kim K. Anti-inflammatory effects of chlorogenic acid in lipopolysaccharide-stimulated RAW 264.7 cells. Inflamm Res. 2014;63(1):81-90.
- Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142(5):687–698. doi:https://doi.org/10.1016/j.cell.2010.07.041.
- Liu Y, XianTao L, Qi H, Ting W, HongBin S, HeYao W. A novel GPR120-selective agonist promotes insulin secretion and improves chronic inflammation. Life Sci. 2021;269(2):119029.
- Christopher L, M VL, Anastasija D, et al. CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction. Aging Cell. 2016;63(1):81-90.
- Grunewald ZI, Lee S, Kirkland R, Ross M, de La Serre CB. Cannabinoid receptor type-1 partially mediates metabolic endotoxemia-induced inflammation and insulin resistance. Physiol Behav. 2019;199(1):282-291.
- Mehrpouya-Bahrami P, Chitrala KN, Ganewatta MS, et al. Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity. Sci Rep. 2017;7(1):15645. doi:https://doi.org/10.1038/s41598-017-15154-6.
- Duncan M, Galic MA, Wang A, et al. Cannabinoid 1 receptors are critical for the innate immune response to TLR4 stimulation. Am J Physiol. Regul Integr Comp Physiol. 2013;305(2):R224-R231.
- Jayarathne S, Stull AJ, Park O‐H, Kim JH, Thompson L, Moustaid‐Moussa N. Protective effects of anthocyanins in obesity‐associated inflammation and changes in gut microbiome. Mol Nutr Food Res. 2019;63(20):1900149. doi:https://doi.org/10.1002/mnfr.201900149.
- Felice C, Lewis A, Armuzzi A, Lindsay JO, Silver A. Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015;41(1):26–38.13008. doi:https://doi.org/10.1111/apt.
- Wang H, Liu D, Ji Y, Liu Y, Xu L, Guo Y. Dietary supplementation of black rice anthocyanin extract regulates cholesterol metabolism and improves gut microbiota dysbiosis in C57BL/6J mice fed a high‐fat and cholesterol diet. Mol Nutr Food Res. 2020;64(8):1900876. doi:https://doi.org/10.1002/mnfr.201900876.
- Baoming T, Jianhua Z, Min Z, Zhifei C, Qingyu M, Huicui L. Lycium ruthenicum anthocyanins attenuate high-fat diet-induced colonic barrier dysfunction and inflammation in mice by modulating the gut microbiota. Mol Nutr Food Res. 2021;65(8):1-16.
- Iio A, Ito M, Itoh T, et al. Molecular hydrogen attenuates fatty acid uptake and lipid accumulation through downregulating CD36 expression in HepG2 cells. Med Gas Res. 2013;3(1):6. doi:https://doi.org/10.1186/2045-9912-3-6.
- Hua-Ying F, Dong Q, Chen Y, et al. Paeonol protects endotoxin-induced acute kidney injury: potential mechanism of inhibiting TLR4-NF-κB signal pathway. Oncotarget. 2016;7(26):39497–39510. doi:https://doi.org/10.18632/oncotarget.8347.
- Yuan Y, Zhou J, Hu R, Zou L, Ji L, Jiang G. Piperine protects against pancreatic β-cell dysfunction by alleviating macrophage inflammation in obese mice. Life Sci. 2021;274:119312. doi:https://doi.org/10.1016/j.lfs.2021.119312.